Zypitamag Now Available for Primary Hyperlipidemia, Mixed Dyslipidemia

Zypitamag is an HMG-CoA reductase inhibitor
Zypitamag is an HMG-CoA reductase inhibitor

Medicure announced the launch of Zypitamag (pitavastatin magnesium) for the treatment of primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet, to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). 

Zypitamag, an HMG-CoA reductase inhibitor, was initially approved by the Food and Drug Administration (FDA) in July 2017. The effect of Zypitamag on cardiovascular morbidity and mortality has not been determined, and it has not been studied in Fredrickson Type I, III, and V dyslipidemias. 

Related Articles

Zypitamag is available in 1mg, 2mg, and 4mg strength tablets in 30-, 90-, 100-, 500-, and 1000-count bottles. Each film-coated tablet contains 1.026mg, 2.053mg, or 4.106mg of pitavastatin magnesium, which is equivalent to 1mg, 2mg, or 4mg, respectively of free base. 

Doses of Zypitamag >4mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies, therefore dosing should not exceed 4mg once daily.

For more information call (800) 509-0544 or visit Zypitamag.com.